Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution, effective June 27, 2025.
The Russell 3000® Index tracks the 3,000 largest U.S. stocks by market cap, while the Russell 2000® measures the 2,000 smallest companies within the Russell 3000®. These widely-used indexes serve as benchmarks for approximately $10.6 trillion in assets. The company's inclusion will result in automatic addition to corresponding growth and value style indexes.
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has granted equity inducements to six new non-officer employees totaling 24,750 share options. The options were granted on June 23, 2025, with an exercise price of $31.49 per common share, matching the closing price on the grant date.
The share options have a four-year vesting schedule, with 25% vesting after one year and the remaining vesting monthly over three years. Each option has a 10-year term and is subject to the company's 2025 Inducement Equity Incentive Plan.
Xenon Pharmaceuticals (NASDAQ:XENE) has appointed Darren Cline as Chief Commercial Officer to lead the company's transition to a commercial-stage organization. Cline brings over 30 years of experience in commercial strategy and operations, notably from his roles at Epygenix Therapeutics and GW Pharmaceuticals, where he successfully commercialized Epidiolex.
Cline will primarily focus on the commercial strategy for azetukalner, Xenon's lead Phase 3 candidate being studied for three indications: epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Phase 3 data is expected in early 2026. The company granted Cline stock options for 185,800 shares at $31.49 per share and 6,200 performance share units as part of his compensation package.
Xenon Pharmaceuticals (Nasdaq: XENE) announced its participation in the upcoming 2025 RBC Capital Markets Global Healthcare Conference in New York. CEO Ian Mortimer will present a fireside chat on Wednesday, May 21, 2025, from 10:30-10:55 AM ET. The presentation will be available via webcast on Xenon's website.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE) has scheduled to release its first quarter 2025 financial results and provide a business update after U.S. market close on Monday, May 12, 2025. The company will host a conference call at 4:30 pm Eastern Time on the same day.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (NASDAQ: XENE) has announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units (PSUs). The grants, effective May 2, 2025, were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $38.28 per common share, vesting over four years with a 10-year term. The PSUs will vest based on achieving predefined milestone-based objectives over approximately three years.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (XENE) has announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025) in San Diego. The company will showcase three key posters, highlighting significant progress in their epilepsy treatment research.
The main focus is on azetukalner, their novel Kv7 potassium channel opener, featuring 36-month long-term data from the ongoing X-TOLE open-label extension study in patients with focal onset seizures (FOS). The data demonstrates sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and a consistent safety profile.
Additional presentations include an exploratory analysis showing reduced seizure frequency across four focal seizure subtypes, and patient survey findings regarding mental health and comorbidity burdens of FOS. The presentations will take place between April 5-9, 2025, with Xenon also hosting booth #1110 in the Exhibit Hall.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
